Value added medicines: what value repurposed medicines might bring to society?

Por Toumi, Mondher, Rémuzat, Cécile
Publicado no J Mark Access Health Policy (2016)

New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France

Por Rémuzat, Cécile, Toumi, Mondher, Falissard, Bruno
Publicado no J Mark Access Health Policy (2013)

New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry

Por Rémuzat, Cécile, Toumi, Mondher, Falissard, Bruno
Publicado no J Mark Access Health Policy (2013)

Market access pathways for cell therapies in France

Por Rémuzat, Cécile, Toumi, Mondher, Jørgensen, Jesper, Kefalas, Panos
Publicado no J Mark Access Health Policy (2015)

Advanced therapy medicinal products: current and future perspectives

Por Hanna, Eve, Rémuzat, Cécile, Auquier, Pascal, Toumi, Mondher
Publicado no J Mark Access Health Policy (2016)

Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials

Por Hanna, Eve, Rémuzat, Cecile, Auquier, Pascal, Toumi, Mondher
Publicado no J Mark Access Health Policy (2016)

Gene therapies development: slow progress and promising prospect

Por Hanna, Eve, Rémuzat, Cécile, Auquier, Pascal, Toumi, Mondher
Publicado no J Mark Access Health Policy (2017)

Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey

Por Angermeyer, Matthias C, Millier, Aurélie, Rémuzat, Cécile, Refaï, Tarek, Toumi, Mondher
Publicado em 2013

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments

Por Massetti, Marc, Aballéa, Samuel, Videau, Yann, Rémuzat, Cécile, Roïz, Julie, Toumi, Mondher
Publicado no J Mark Access Health Policy (2015)

Key drivers for market penetration of biosimilars in Europe

Por Rémuzat, Cécile, Dorey, Julie, Cristeau, Olivier, Ionescu, Dan, Radière, Guerric, Toumi, Mondher
Publicado no J Mark Access Health Policy (2017)

Overview of external reference pricing systems in Europe

Por Rémuzat, Cécile, Urbinati, Duccio, Mzoughi, Olfa, El Hammi, Emna, Belgaied, Wael, Toumi, Mondher
Publicado no J Mark Access Health Policy (2015)

Current process and future path for health economic assessment of pharmaceuticals in France

Por Toumi, Mondher, Rémuzat, Cécile, El Hammi, Emna, Millier, Aurélie, Aballéa, Samuel, Chouaid, Christos, Falissard, Bruno
Publicado no J Mark Access Health Policy (2015)

French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends

Por Chouaid, Christos, Borget, Isabelle, Braun, Eric, Bazil, Marie-Laure, Schaetz, Dominique, Rémuzat, Cécile, Toumi, Mondher
Publicado no Target Oncol (2016)

Pharmaceutical expenditure forecast model to support health policy decision making

Por Rémuzat, Cécile, Urbinati, Duccio, Kornfeld, Åsa, Vataire, Anne-Lise, Cetinsoy, Laurent, Aballéa, Samuel, Mzoughi, Olfa, Toumi, Mondher
Publicado no J Mark Access Health Policy (2014)

Novel methodology for pharmaceutical expenditure forecast

Por Vataire, Anne-Lise, Cetinsoy, Laurent, Aballéa, Samuel, Rémuzat, Cécile, Urbinati, Duccio, Kornfeld, Åsa, Mzoughi, Olfa, Toumi, Mondher
Publicado no J Mark Access Health Policy (2014)

EU pharmaceutical expenditure forecast

Por Urbinati, Duccio, Rémuzat, Cécile, Kornfeld, Åsa, Vataire, Anne-Lise, Cetinsoy, Laurent, Aballéa, Samuel, Mzoughi, Olfa, Toumi, Mondher
Publicado no J Mark Access Health Policy (2014)

Difference of perceptions and evaluation of cognitive dysfunction in major depressive disorder patients across psychiatrists internationally

Por Hammi, Emna El, Samp, Jennifer, Rémuzat, Cécile, Auray, Jean-Paul, Lamure, Michel, Aballéa, Samuel, Kooli, Amna, Akhras, Kasem, Toumi, Mondher
Publicado em 2014